Biomarkers of therapeutic response with immune checkpoint inhibitors
نویسندگان
چکیده
منابع مشابه
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
BACKGROUND Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20-40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and high costs. This urges the development of predictive biomarkers for ICI response to select patient...
متن کاملImmune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer.
Breast cancer is one of the major threats to female health, and its incidence is rapidly increasing in many countries. Currently, breast cancer is treated with surgery, followed by chemotherapy or radiation therapy, or both. However, a substantial proportion of breast cancer patients might have a risk for local relapse that leads to recurrence of their disease and/or metastatic breast cancer. T...
متن کاملAssessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors.
BACKGROUND Immunotherapeutic agents, especially checkpoint inhibitors, have emerged as the mainstay of therapy for several solid and hematological malignancies. These therapies are under investigation for the treatment of high-grade gliomas and brain metastases. METHODS This article reviews the unique challenges encountered when evaluating changes on magnetic resonance imaging (MRI) of gliobl...
متن کاملCardiotoxicity of immune checkpoint inhibitors
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies. Cancer immunotherapy with immune checkpoint blockers (ie, monocl...
متن کامل[Management of Toxicities of Immune Checkpoint Inhibitors].
Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab, the anti-PD-1 antibodies nivolumab and pembrolizumab, and the anti-PD-L1 antibody atezolizumab had produced long-lasting tumor responses in several malignancies. Immune-related Adverse Events(irAEs)which are different from adverse events of conventional chemotherapy and molecular targeted therapy, occur as a consequenc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Translational Medicine
سال: 2021
ISSN: 2305-5839,2305-5847
DOI: 10.21037/atm-20-6396